Gemcitabine-Capecitabine Chemotherapy Plus Intra- Arterial Epirubicin-Cisplatin in Pancreatic Cancer Patients after FOLFIRINOX First Line Chemotherapy: A Retrospective Analysis
Journal Title: Journal of Cancer Sciences - Year 2016, Vol 3, Issue 1
Abstract
Background: Most pancreatic cancer patients have disease recurrence/progression within 6 months from firstline chemotherapy end. Today, there is no a standard of care of second-line therapy. Materials (patients) and methods: We retrospectively collected data of 41 locally advanced/metastatic pancreatic cancer patients underwent to FOLFIRINOX first line chemotherapy and subsequently treated with Gemcitabine-Capecitabine chemotherapy plus Intraarterial Epirubicin-Cispatin (EC-GEMCAP). Results: Treatment was well tolerated, without dose reductions or delays. Hematologic and no hematologic grade 3-4 toxicities were 39% and 12.2%. Twenty, 2 and 12 patients obtained a stability/partial response/progression disease respectively, with a disease control rate in 22 patients. One patient with locally advanced disease underwent to radically surgery after 6 cycles of EC-GEMCAP. Median OS was 16.9 months (95% CI: 14.7-19.0) with OS rates at 6, 12 and 24 months of 95.1%, 80.5% and 31.7%. As regards second-line therapy, median OS was 8.9 months (95% CI: 6.9-10.9). OS rates at 6, 12 and 24 months were 61%, 80.5% and 31.7%. EC-GEMCAP median PFS was 4.1 months (95% CI: 3.1-5.1).PFS rates at 6 and 12 months were 41.5% and 19.5%. Conclusions: EC-GEMCAP proved to be a viable treatment in terms of toxicity and activity and it could be considered a therapeutic option also in poor performance status patients.
Authors and Affiliations
Ginocchi Laura
Keywords
Related Articles
- EP ID EP209359
- DOI 10.13188/2377-9292.1000011
- Views 104
- Downloads 0
N-Hydroxy-6-(5-Nitro-Naphtalimide)-Hexanamide Inhibits Lysine Deacetylation, Mitigates Angiogenesis and Reduces Tumor Growth
In this report, we present a novel histone deacetylase inhibitor (HDACi) (N-Hydroxy-6-(5-nitro-naphtalimide)-hexanamide: ES8) that efficiently inhibits angiogenesis in relevant ex vivo models (Human umbilical vein endoth...
Targeting Pancreatic Cancer Stem Cells
Carcinomas of an epithelial-origin account for the majority of all malignant cancers worldwide. As the most common pancreatic cancer, Pancreatic Ductal Adeno Carcinoma (PDAC) is a carcinoma with an extremely high lethali...
White Adipose Tissue Browning and Cancer Cachexia
Cachexia or wasting syndrome is often seen in cancer patients. Over half of the patients suffer from this condition although the incidence varies from tumor types. Symptoms of cancer cachexia include progressive weight l...
Massive Intra-Tumor Hemorrhage during Induction Chemotherapy in Neuroblastoma: A Case Series Report
We describe 5 children with high risk neuroblastoma (NB) who, during the induction phase of therapy, were admitted with circulatory shock because of massive intra-tumor bleeding. Patient’s intensive supportive care with...
High Dose Vitamin C and Low Dose Chemo Treatment
Research has shown that intravenous high dose vitamin C in cancer therapy cannot be dismissed but that it warrants further investigation. Recent studies have made more inroads into the understanding of the role of vitami...